Literature DB >> 25033841

Extrinsic apoptosis is impeded by direct binding of the APL fusion protein NPM-RAR to TRADD.

Anuja Chattopadhyay1, Brian L Hood2, Thomas P Conrads2, Robert L Redner3.   

Abstract

UNLABELLED: A subset of acute promyelocytic leukemia (APL) cases has been characterized by the t(5;17)(q35;q21) translocation variant, which fuses nucleophosmin (NPM) to retinoic acid receptor α (RARA). The resultant NPM-RAR fusion protein blocks myeloid differentiation and leads to a leukemic phenotype similar to that caused by the t(15;17)(q22;q21) PML-RAR fusion. The contribution of the N-terminal 117 amino acids of NPM contained within NPM-RAR has not been well studied. As a molecular chaperone, NPM interacts with a variety of proteins implicated in leukemogenesis. Therefore, a proteomic analysis was conducted to identify novel NPM-RAR-associated proteins. TNF receptor type I-associated DEATH domain protein (TRADD) was identified as a relevant binding partner for NPM-RAR. This interaction was validated by coprecipitation and colocalization analysis. Biologic assessment found that NPM-RAR expression impaired TNF-induced signaling through TRADD, blunting TNF-mediated activation of caspase-3 (CASP3) and caspase-8 (CASP8), to ultimately block apoptosis. IMPLICATIONS: This study identifies a novel mechanism through which NPM-RAR affects leukemogenesis. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25033841      PMCID: PMC4163521          DOI: 10.1158/1541-7786.MCR-14-0080

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  44 in total

Review 1.  Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia.

Authors:  A Melnick; J D Licht
Journal:  Blood       Date:  1999-05-15       Impact factor: 22.113

Review 2.  PML nuclear bodies and apoptosis.

Authors:  Yuki Takahashi; Valérie Lallemand-Breitenbach; Jun Zhu; Hugues de Thé
Journal:  Oncogene       Date:  2004-04-12       Impact factor: 9.867

3.  Differentiation of t(5;17) variant acute promyelocytic leukemic blasts by all-trans retinoic acid.

Authors:  R L Redner; S J Corey; E A Rush
Journal:  Leukemia       Date:  1997-07       Impact factor: 11.528

4.  The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts.

Authors:  U Testa; F Grignani; P Samoggia; C Zanetti; R Riccioni; F Lo Coco; D Diverio; N Felli; C G Passerini; M Grell; P G Pelicci; C Peschle
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

5.  Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia.

Authors:  R A Wells; C Catzavelos; S Kamel-Reid
Journal:  Nat Genet       Date:  1997-09       Impact factor: 38.330

6.  A PMLRARalpha transgene initiates murine acute promyelocytic leukemia.

Authors:  D Brown; S Kogan; E Lagasse; I Weissman; M Alcalay; P G Pelicci; S Atwater; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

7.  The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion.

Authors:  R L Redner; E A Rush; S Faas; W A Rudert; S J Corey
Journal:  Blood       Date:  1996-02-01       Impact factor: 22.113

8.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

9.  The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1.

Authors:  N Yoneda-Kato; A T Look; M N Kirstein; M B Valentine; S C Raimondi; K J Cohen; A J Carroll; S W Morris
Journal:  Oncogene       Date:  1996-01-18       Impact factor: 9.867

10.  Interaction with RXR is necessary for NPM-RAR-induced myeloid differentiation blockade.

Authors:  Elizabeth A Rush; Sheri L Pollock; Irina Abecassis; Robert L Redner
Journal:  Leuk Res       Date:  2013-09-29       Impact factor: 3.156

View more
  4 in total

1.  The leukemic oncoprotein NPM1-RARA inhibits TP53 activity.

Authors:  Erin M Swaney; Anuja Chattopadhyay; Irina Abecassis; Elizabeth A Rush; Robert L Redner
Journal:  Leuk Lymphoma       Date:  2016-01-12

2.  NPM-RAR binding to TRADD selectively inhibits caspase activation, while allowing activation of NFκB and JNK.

Authors:  Anuja Chattopadhyay; Irina Abecassis; Robert L Redner
Journal:  Leuk Lymphoma       Date:  2015-10-05

Review 3.  Current views on the genetic landscape and management of variant acute promyelocytic leukemia.

Authors:  Xiang Zhang; Jiewen Sun; Wenjuan Yu; Jie Jin
Journal:  Biomark Res       Date:  2021-05-06

Review 4.  Nucleophosmin: from structure and function to disease development.

Authors:  Joseph K Box; Nicolas Paquet; Mark N Adams; Didier Boucher; Emma Bolderson; Kenneth J O'Byrne; Derek J Richard
Journal:  BMC Mol Biol       Date:  2016-08-24       Impact factor: 2.946

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.